In vitro activity and pharmacodynamics of oral β-lactam antibiotics against Streptococcus pneumoniae from Southeast Missouri

Pharmacotherapy

Volumn 19, Issue 11 I, 1999, Pages 1308-1314

  Kays, Michael B ^a   Wood, Karriann K ^a   Miles, Donald O ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CLAVULANIC ACID; LORACARBEF; PENICILLIN G;

ANTIMICROBIAL ACTIVITY; ARTICLE; CASE REPORT; CHILD; DRUG POTENCY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PHARMACODYNAMICS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032752510     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.16.1308.30869     Document Type: Article

References (53)

1. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
2. Appelbaum PC. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1996;15:932-9.
3. Spika JS, Facklam RR, Plikaytis BD, et al. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis 1991;163:1273-8.
4. Thornsberry C, Brown SD, Yee YC, et al. Increasing penicillin resistance in Streptococcus pneumoniae in the US. Infect Med 1993;10(suppl D):S15-24.
5. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:1208-13.
6. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998;27:764-70.
7. Jacobs MR, Bajaksouzian S, Lin G, Appelbaum PC. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to oral agents: results of a 1997 epidemiologic study [abstr]. In: Programs and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA. Washington, DC: American Society for Microbiology, 1998.
8. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995;99(suppl 6B):3S-7.
9. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997;29:249-57.
10. Mason EO, Kaplan SL. Penicillin-resistant pneumococci in the United States. Pediatr Infect Dis J 1995;14:1017-18.
11. Jacobs MR, Bajaksouzian S, Lin G, Appelbaum PC. Variation in antimicrobial resistance of community isolates of Streptococcus pneumoniae by age, region, and disease [abstr]. In: Programs and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego, CA. Washington, DC: American Society for Microbiology, 1998.
12. Rauch AM, O'Ryan M, Van R, Pickering LK. Invasive disease due to multiply resistant Streptococcus pneumoniae in a Houston, Texas, day-care center. Am J Dis Child 1990;144:923-7.
13. Welby PL, Keller DS, Cromien JL, Tebas P, Storch GA. Resistance to penicillin and non-beta-lactam antibiotics of Streptococcus pneumoniae at a children's hospital. Pediatr Infect Dis J 1994;13:281-7.
14. Pikis A, Akram S, Donkersloot JA, Campos JM, Rodriguez WJ. Penicillin-resistant pneumococci from pediatric patients in the Washington, DC, area. Arch Pediatr Adolesc Med 1995;149:30-5.
15. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-6.
16. CDC. Drug-resistant Streptococcus pneumoniae - Kentucky and Tennessee, 1993. MMWR 1993;43:23-31.
17. Duchin JS, Breiman RF, Diamond A, et al. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. Pediatr Infect Dis J 1995;14:745-50.
18. Vogelman B, Gudmundsson S, Leggett J, Tumidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
19. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
20. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
21. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996;25:213-17.
22. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998;42:2375-9.
23. Woodnutt G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:29-34.
24. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
25. Ginsburg CM, McCracken GH, Zweighaft TC, Clahsen JC. Comparative pharmacokinetics of cyclacillin and amoxicillin in infants and children. Antimicrob Agents Chemolher 1981;19:1086-8.
26. Nelson JD, Kusmiesz H, Shelton S. Pharmacokinetics of potassium clavulanate in combination with amoxicillin in pediatric patients. Antimicrob Agents Chemother 1982;21:681-2.
27. Schaad UB, Casey PA, Cooper DL. Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients. Antimicrob Agents Chemother 1983;23: 252-5.
28. Van Njekerk CH, van den Ende J, Hundt HKL, Louw EA. Pharmacokinetic study of a pediatric formulation of amoxycillin and clavulanic acid in children. Eur J Clin Pharmacol 1985;29:235-9.
29. Schaad UB, Casey PA, Ravenscroft AT. Pharmacokinetics of a syrup formulation of amoxycillin-potassium clavulanate in children. J Antimicrob Chemother 1986;17:341-5.
30. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J 1996;15:949-54.
31. Saez-Llorens X, Shyu WC, Shelton S, Kumiesz H, Nelson J. Pharmacokinetics of cefprozil in infants and children. Antimicrob Agents Chemother 1990;34:2152-5.
32. Shyu WC, Haddad J, Reilly J, et al. Penetration of cefprozil into middle ear fluid of patients with otitis media. Antimicrob Agents Chemother 1994;38:2210-12.
33. Ginsburg CM, McCracken GH, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985;28:504-7.
34. Powell DA, James NC, Ossi MJ, Nahata MC, Donn KH. Pharmacokinetics of cefuroxime axetil suspension in infants and children. Antimicrob Agents Chemother 1991;35:2042-5.
35. Haddad J, Isaacson G, Respler DS, et al. Concentration of cefuroxime in serum and middle ear effusion after single dose treatment with cefuroxime axetil. Pediatr Infect Dis J 1991;10:294-8.
36. Kearns GL, Darville T, Wells TG, Jacobs RF, Hughes GS, Borin MT. Single dose pharmacokinetics of cefpodoxime proxetil in infants and children. Drug Invest 1994;7:221-33.
37. Kearns GL, Abdel-Rahman SM, Jacobs RF, Wells TG, Borin MT. Cefpodoxime pharmacokinetics in children: effect of food. Pediatr Infect Dis J 1998;17:799-804.
38. McCracken GH, Ginsburg CM, Clahsen JC, Thomas ML. Pharmacokinetics of cefaclor in infants and children. J Antimicrob Chemother 1978;4:515-21.
39. Ginsburg CM. Comparative pharmacokinetics of cefadroxil, cefaclor, cephalexin, and cephradine in infants and children. J Antimicrob Chemother 1982;10(suppl B):27-31.
40. Nelson JD, Shelton S, Kusmiesz H. Pharmacokinetics of LY163892 in infants and children. Antimicrob Agents Chemother 1988;32:1738-9.
41. Nahata MC, Koranyi KI. Pharmacokinetics of loracarbef in pedialric patients. Eur J Drug Metab Pharmacokinet 1992;17:201-4.
42. DeSante KA, Zeckel ML. Pharmacokinetic profile of loracarbef. Am J Med 1992;92(suppl 6A):16S-19.
43. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: M100-S7. Villanova, PA: NCCLS, 1997.
44. Poole MD. Implications of drug-resistant Streptococcus pneumoniae for otitis media. Pediatr Infect Dis J 1998;17:953-6.
45. White RL, Kays MB, Friedrich LV, Del Bene VE. Impact of different statistical methodologies on the evaluation of the in vitro MICs for Bacteroides fragilis of selected cephalosporins and cephamycins. J Antimicrob Chemother 1993;31:57-64.
46. Klein JO. Clinical implications of antibiotic resistance for management of acute otitis media. Pediatr Infect Dis J 1998;17:1084-9.
47. Block SL, Harrison CJ, Hedrick JA, et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J 1995;14:751-9.
48. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J 1996;15:940-3.
49. McLinn S, Williams D. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media. Pediatr Infect Dis J 1996;15:S3-9.
50. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother 1998;42:589-95.
51. Jacobs MR. Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: overview and update. Pediatr Infect Dis J 1998;17:947-52.
52. Blumer JL. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media. Pediatr Infect Dis J 1998;17:1070-5.
53. Bottenfield GW, Burch DJ, Hedrick JA, Schaten R, Rowinski CA, Davies JT. Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1998;17:963-8.